PAG
KYMR icon

Private Advisor Group’s Kymera Therapeutics KYMR Stock Holding History

Private Advisor Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$270K Hold
3,239
– – ﹤0.01% 2262
2025
Q4 		$252K Buy
+3,239
New +$219K ﹤0.01% 2272

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Private Advisor Group's KYMR Position: Q1 2026 in Review

Private Advisor Group held its Kymera Therapeutics (KYMR) position steady in Q1 2026 at 3,239 shares worth $270K. The position accounts for ﹤0.01% of the portfolio, ranked #2262.

Private Advisor Group first reported a position in KYMR in Q4 2025 and has held it in 2 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Private Advisor Group held 3,239 shares of Kymera Therapeutics worth $270K as of Q1 2026.
  • Private Advisor Group left its Kymera Therapeutics share count unchanged in Q1 2026.
  • Kymera Therapeutics made up ﹤0.01% of Private Advisor Group's portfolio in Q1 2026, its #2262 holding.
  • Private Advisor Group first reported a position in Kymera Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Private Advisor Group's 13F filing for Q1 2026, filed 27 Apr 2026.